# US 11,998,609 B2 · Self-assembling antiviral prodrugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,998,609 B2
- Document ID: US11998609B2
- Status: Granted
- Kind: B2
- Application number: 17/981,595
- Filed: 2022-11-07
- Published: 2023-05-11
- Granted: 2024-06-04
- Earliest claimed: 2021-11-08
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Honggang Cui; Charles Williams Flexner; Maya Monroe; Han Wang
- Web page: https://patentgrep.com/patent/US11998609B2

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/6903: {the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are therapeutic self-assembling molecules including a peptide sequence conjugated to one or more antiviral therapeutics to form a peptide-based antiviral prodrug capable of self-assembly into supramolecular structures with varying morphology in aqueous solutions, which can be injected subcutaneously or intramuscularly for the long-acting treatment of chronic viral infections.

## Claims

### Claim 1

A composition comprising a peptide-based antiretroviral therapeutic (ARV) prodrug selected from the group consisting of:

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition further comprises a hydrophobic moiety encapsulated within a hydrophobic core of the composition.

### Claim 3 (depends on 1)

A method for treating a viral infection in a subject in need thereof, wherein the method comprises administering to said subject a therapeutically effective amount of a composition of claim 1, and wherein said viral infection is selected from a retroviral infection or a hepatitis B viral infection.

### Claim 4 (depends on 3)

The method of claim 3, wherein said viral infection is a chronic viral infection.

### Claim 5 (depends on 3)

The method of claim 3, wherein said viral infection is a hepatitis B viral infection.

### Claim 6 (depends on 3)

The method of claim 3, wherein said viral infection is a human immunodeficiency virus (HIV) infection.

### Claim 7 (depends on 3)

The method of claim 3, wherein the composition is administered by subcutaneous or intramuscular injection.

### Claim 8 (depends on 3)

The method of claim 3, wherein the subject has a hepatitis B viral infection or acquired immune deficiency syndrome (AIDS).